Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark ...
Optune Lua, formerly known as NovoTTF-100L, is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) ...
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) Optune Lua is now approved for use concurrently with ...
Optune Lua adoption lag hit shares, but 2026 catalysts and $230M net cash could drive a rebound. Know more about NVCR stock ...
Novocure (NASDAQ:NVCR), a company focused on developing new treatments for solid tumors, on Oct. 16 announced that the U.S. based FDA has approved their Optune Lua device for NSCLC metastatic cancer ...
The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or ...
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Optune Lua is the brand name for the NovoTTF-100L System in malignant pleural mesothelioma (MPM). The U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback